Accredited Investors Inc. Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Accredited Investors Inc. grew its position in Verve Therapeutics, Inc. (NASDAQ:VERV) by 14.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,000 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Accredited Investors Inc.’s holdings in Verve Therapeutics were worth $97,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in shares of Verve Therapeutics by 908.4% in the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after buying an additional 6,949 shares during the last quarter. Creative Planning acquired a new position in Verve Therapeutics in the 3rd quarter worth approximately $50,000. PFG Investments LLC purchased a new position in Verve Therapeutics during the 3rd quarter worth approximately $53,000. Daiwa Securities Group Inc. boosted its holdings in shares of Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after acquiring an additional 5,723 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. increased its stake in shares of Verve Therapeutics by 13.5% in the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after acquiring an additional 1,778 shares during the period. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Analyst Ratings Changes

VERV has been the subject of a number of research reports. Canaccord Genuity Group boosted their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright decreased their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Royal Bank of Canada dropped their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th.

Verve Therapeutics Stock Performance

Shares of NASDAQ VERV opened at $4.79 on Monday. The company has a market capitalization of $405.52 million, a PE ratio of -1.95 and a beta of 1.75. The company’s fifty day moving average price is $5.45 and its 200 day moving average price is $5.67. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. During the same period in the prior year, the company posted ($0.72) EPS. The company’s revenue for the quarter was up 120.2% on a year-over-year basis. On average, equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.